Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524726 · ClinicalTrials.gov registry record
The International PNH Interest Group PNH Registry
A clinical trial of Paroxysmal Nocturnal Hemoglobinuria, sponsored by International PNH Interest Group.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT06524726 is a study of Paroxysmal Nocturnal Hemoglobinuria that is actively recruiting participants, run by International PNH Interest Group. The registered enrollment target is 2,000 participants, above the 122-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (1539% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06524726, a study of Paroxysmal Nocturnal Hemoglobinuria, is actively recruiting participants, sponsored by International PNH Interest Group.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this International PNH Interest Group (IPIG) registry is to develop an international database to prospectively collect data on patients with PNH covering clinical outcomes, patient reported outcomes (PROs), and health-resource utilization (HRU) on all enrolled patients, as well as long term safety data.
Conditions Studied
Study Locations (1)
Florida
- International PNH Interest Group - Altamonte Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-05-10 |
| Est. Completion | 2029-05-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06524726
The ClinicalTrials.gov registry entry for NCT06524726 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 122-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (1539% higher). The listed sponsor is International PNH Interest Group, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 0 interventions.
NCT06524726 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06524726 about?
NCT06524726 is a clinical study titled "The International PNH Interest Group PNH Registry". The aim of this International PNH Interest Group (IPIG) registry is to develop an international database to prospectively collect data on patients with PNH covering clinical outcomes, patient reported outcomes (PROs), and health-resource utilization (HRU) on all enrolled patients, as well as long te...
What is the current status of trial NCT06524726?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-05-10. Estimated completion is 2029-05-10.
What conditions does trial NCT06524726 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria.
Who is sponsoring clinical trial NCT06524726?
This trial is sponsored by International PNH Interest Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06524726 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Reported Outcomes in PNH
RECRUITING
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
Global PNH Patient Registry
RECRUITING
-
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RECRUITING · Phase 2
-
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
ACTIVE NOT RECRUITING
-
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.